anayamalik, Author at European Medical Journal - Page 68 of 83

Genomic Test Guides Breast Cancer Therapy Duration

A recent analysis of the IDEAL clinical trial highlights a breakthrough for early-stage breast cancer.

Cancer Risk Elevated in Multiple Sclerosis: New Findings

Patients with multiple sclerosis (MS) may experience a slightly increased risk of developing cancer compared to the general population, according to a new nationwide French study spanning 10 years.

OSA Severity Linked to Postoperative Complications

Obstructive sleep apnea (OSA) severity may hold the key to predicting postoperative cardiorespiratory complications, according to a new study involving over 6,700 patients.

Hydrocortisone Fiber Patch: A 24-Hour Skin Solution

A cutting-edge alternative to traditional skin creams offers a promising new approach for treating inflammatory skin diseases.

New Pathway for OA Treatment: ACR24

Sodium channels in cartilage cells may hold the key to treating osteoarthritis (OA), a new study presented at ACR Convergence 2024 unveiled.

Workload Control Linked to Physician Burnout

Control over clinical work plays a critical role in preventing burnout and retaining U.S. physicians, as highlighted in a new study.

Colorectal Cancer Stool Testing in Underserved Communities

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.

Clonazepam Recall Due To Strength Mislabeling

Clonazepam has been recalled due to potential product carton strength mislabeling. Endo Pharmaceuticals (Malvern, Pennsylvania) has issued a voluntary, nationwide recall of a specific lot of Clonazepam Orally Disintegrating Tablets (USP, C-IV).

How Medical AI Bias Risks Patient Care

Bias in medical artificial intelligence (AI) poses a critical threat to equitable patient outcomes, according to recent research.

How Gut Bacteria Impact Tamoxifen Therapy

The response to tamoxifen, a cornerstone drug in preventing breast cancer recurrence, may hinge on an unexpected factor: gut bacteria.